The efficacy of Paclitaxel on solid tumour analysed by ATP bioluminescence assay and VEGF expression: A translational research study

Biomedicine and Pharmacotherapy

Volumn 59, Issue SUPPL. 2, 2005, Pages

  Loo, W T Y ^a   Fong, J H M ^a   Cheung, M N B ^a   Chow, L W C ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ATP bioluminescence assay; Metastasis; Paclitaxel

Indexed keywords

ADENOSINE TRIPHOSPHATE; PACLITAXEL; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BIOLUMINESCENCE; CANCER DIAGNOSIS; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; INVASIVE CARCINOMA; METABOLIC RATE; METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION;

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUMINESCENT MEASUREMENTS; NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644534873     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(05)80069-1     Document Type: Article

References (24)

1. Rahman M.A., and Toi M. Anti-angiogenic therapy in breast cancer Biomed Pharmacother 57 2003 463 470
2. Weidner N., Folkman J., Pozza F., Bevilacqua P., Alfred E.N., Moore D.H., Meli S., and Gasparin G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma J Natl Cancer Inst 84 1992 1875 1887
3. Toi M., Kashitani J., and Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma Int J Cancer 55 1993 371 374
4. Niethammer A.G. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth Nat Med 8 2002 1369 1375
5. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 1990 4 6
6. Zhong X.S., Zheng J.Z., Reed E., and Jiang B.H. SU5416 inhibited VEGF and HIF-lalpha expression through the PI3K/AKT/p70S6K1 signaling pathway Biochem Biophys Res Commun 324 2004 471 480
7. Horwitz S.B. Mechanism of action of taxol Trends Pharmacol Sci. 13 1992 134 136
8. Spencer C.M., and Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer Drugs 48 1994 794 847
9. Rowinsky E.K., and Donehower R.C. Paclitaxel (taxol) N Engl J Med 332 1995 1004 1014
10. Jordan M.A., and Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy Curr Opin Cell Biol 10 1998 123 130
11. Blagosklonny M.V., and Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review) Int J Cancer 83 1999 151 156
12. Giannakakou P., Robey R., Fojo T., and Blagosklonny M.V. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity Oncogene 20 2001 3806 3813
13. Huang G.C., Liu S.Y., Lin M.H., Kuo Y.Y., and Liu Y.C. The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma Jpn J Clin Oncol 34 2004 499 504
14. Perol M. First-line treatment of metastatic non-small cell lung cancers Rev Pneumol Clin 60 2004 51 56
15. Sit A.S., Kelley J.L., Gallion H.H., Kunschner A.J., and Edwards R.P. Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix Cancer Invest 22 2004 368 373
16. Dec 31. Tse E.Y., Loo W.T., Cheung M.N., Chow L.W., and Cheng C.W. Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence Life Sci 76 7 2004 827 834
17. Boabang P., Kurbacher C.M., Kohlhagen H., Waida A., and Amo-Takyi B.K. Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay Anticancer Drugs 1 2000 843 848
18. Kochli O.R., Sevin B.U., Schar G., and Haller M. Value of the adenosine triphosphate chemosensitivity assay for pre-therapeutic determination of the chemosensitivity of breast cancer cells in cell culture Geburtshilfe Frauenheilkd 55 1995 7 16
19. Furukawa T., Kubota T., Tanino H., Oura S., Yuasa S., Murate H., Morita K., Kozakai K., Yano T., and Hoffman R.M. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay Anticancer Res 20 2000 3657 3658
20. Kurbacher C.M., Grecu O.M., Stier U., Gibster T.J., Janat M.M., Untch M., Konecny G., Bruckner H.W., and Cree I.A. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Recent results Cancer Res 161 2003 221 230
21. Zhou J., Liu M., Aneja R., Chandra R., and Joshi H.C. Enhancement of paclitaxel-induced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-targeting agent EM012 Biochem Pharmacol 68 2004 2435 2441
22. Sui M., Dziadyk J.M., Zhu X., and Fan W. Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy Clin Cancer Res 10 2004 4848 4857
23. Konecny G.E., Meng Y.G., and Untch M. Association between HER2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients Clin Cancer Res 10 2004 1706 1716
24. Locopo N., Fanelli M., and Gasparini G. Clinical significance of angiogenic factors in breast cancer Breast Cancer Res Treat 52 1-3 1998 159 173